Predicting response to first-line DLBCL treatment using ctDNA and PET/CT

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter, multi-cohort study enrolling about 80 adults with newly diagnosed, CD20‑positive DLBCL who have not received prior systemic therapy. Participants are stratified by baseline International Prognostic Index (IPI) and receive six cycles of either R‑CHOP or Pola‑R‑CHP, with PET/CT at baseline, Cycle 2 Day 20, and six weeks after Cycle 6 Day 21. Whole-blood samples for circulating tumor DNA (ctDNA) are collected at baseline, Cycle 3 Day 1, and six weeks after Cycle 6 Day 21 to compare molecular response with imaging. The primary aim is to see if PET and ctDNA results after two cycles are associated with progression-free survival, with secondary endpoints including remission rates and correlation of combined testing with treatment outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years old.
* Previously untreated CD20-positive DLBCL patients, including the following types according to the 2016 WHO classification of lymphoid neoplasms: DLBCL, not otherwise specified (NOS) including germinal center B-cell type and activated B-cell type; T-cell/histiocyte-rich large B-cell lymphoma; Epstein - Barr virus-positive DLBCL, NOS; ALK-positive large B-cell lymphoma; HHV8-positive DLBCL, NOS; high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (double-hit or triple-hit lymphoma); high-grade B-cell lymphoma, NOS.
* Signed informed consent form (ICF).
* Eastern Cooperative Oncology Group (ECOG) performance status score 0 - 2, with an expected survival greater than 12 months.
* Have at least one measurable two-dimensional lesion determined by clinical examination, CT scan, or MRI: ① lymph nodes \> 1.5 cm; ② other non-lymph node lesions ≥ 1.0 cm.
* Good function of major organs: Hematological function: absolute neutrophil count ≥ 1,000/mm³, platelet count ≥ 75,000/mm³; Liver function: ALT/AST \< 3 times the upper limit of normal (ULN) and total bilirubin ≤ 1.5× ULN (for patients with Gilbert syndrome, hilar compressive adenopathy-induced cholestasis, liver involvement or lymphoma-induced biliary obstruction \< 5 times ULN); Renal function: creatinine clearance \> 30 mL/min, creatinine ≤ 1.5× ULN; Pulmonary function: indoor oxygen saturation ≥ 95%; Cardiac function: no obvious cardiac insufficiency or cardiovascular disease.
* Fertile patients must be willing to take highly effective contraceptive measures during the study and within 120 days after the last administration of treatment.

Exclusion Criteria:

* Patients planned to receive short-cycle chemotherapy and radiotherapy.
* Subjects judged by the investigator to have any factors affecting compliance with the protocol, including uncontrollable medical, psychological, family, sociological or geographical conditions; or unwilling or unable to comply with the procedures required in the study protocol.
* Known human immunodeficiency virus (HIV) infection or positive immunassay.
* Viral infections that cannot be controlled by antiviral drugs, such as herpesvirus active infection, acute or chronic active hepatitis B, acute or chronic active hepatitis C, etc. (Note: Chronic HBV carriers or inactive HBsAg-positive subjects with HBV-DNA below the detection limit can be enrolled, requiring clinical evaluation, and if appropriate, preventive antiviral treatment is required; HCV antibody-negative subjects can be enrolled, and HCV antibody-positive patients need to be tested for HCV-RNA, and if negative, they can be enrolled).
* Patients with uncontrolled lymphoma central nervous system infiltration (central nervous system diseases diagnosed at the initial diagnosis are allowed, provided that complete remission of central nervous system diseases is achieved and maintained and there is no central nervous system disease at recurrence).
* Pregnant or lactating patients.
* Other concurrent serious diseases or medical conditions that would interfere with participation in the study.

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Rong Tao, M.D
• Email: rtao@shca.org.cn
• Phone: 86-21-64175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Treatment for elderly patients with DLBCL who can't tolerate chemotherapy

  This study is testing a new combination treatment for older patients with diffuse large B-cell lymphoma who can't handle traditional chemotherapy to see if it can help them.

  Recruiting Phase 2 First Affiliated Hospital of Ningbo University · Ningbo, Zhejiang · NCT06758037

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Treatment for relapsed or refractory diffuse large B-cell lymphoma using zilovertamab vedotin

  This study is testing a new treatment called zilovertamab vedotin for adults with relapsed or refractory diffuse large B-cell lymphoma to see if it works better than standard care.

  Recruiting at 43 sites Phase 2/3 Merck Sharp & Dohme LLC · Glendale, Arizona and 134 other locations · NCT05139017

• Comparing two treatments for elderly patients with diffuse large B-cell lymphoma

  This study is testing whether a new treatment for elderly patients with diffuse large B-cell lymphoma works better than the standard treatment.

  Recruiting at 52 sites Phase 3 Nordic Lymphoma Group · Albury and 68 other locations · NCT04332822

• Combining acalabrutinib with standard chemotherapy for untreated aggressive B-cell lymphoma

  This study is testing if adding a new drug called acalabrutinib to standard chemotherapy can help people with untreated aggressive B-cell lymphoma get better results.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT04002947

• Polatuzumab Vedotin plus Rituximab with Reduced-dose chemo for frail seniors with DLBCL

  This trial tests whether a gentler, first-line treatment (Polatuzumab Vedotin with Rituximab and reduced-dose chemo) helps older, frail patients with DLBCL stay disease-free longer.

  Recruiting Phase 4 The First Hospital of Jilin University · Changchun, Jilin · NCT07908888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.